Source comparison
PT-141 Alternative to Viagra: Full Mechanism Comparison
Primary Mechanism Melanocortin MC3R/MC4R receptor agonist in hypothalamus and limbic system Phosphodiesterase-5 inhibitor in penile smooth muscle tissue PT-141 acts centrally on arousal signaling; Viagra acts peripherally on vascular function Route of Administ
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Melanocortin MC3R/MC4R receptor agonist in hypothalamus and limbic system
- Phosphodiesterase-5 inhibitor in penile smooth muscle tissue
- PT-141 acts centrally on arousal signaling; Viagra acts peripherally on vascular function
- Route of Administration
- Subcutaneous injection (autoinjector pen). 1.75mg dose
- Oral tablet. 25mg, 50mg, or 100mg dose
- PT-141 requires self-injection; Viagra is taken as needed orally 30–60 minutes before activity
- Onset Time
- 45–90 minutes (peak plasma levels at 60 minutes)
- 30–60 minutes (peak plasma levels at 60–90 minutes on empty stomach)
- Both require advance planning; Viagra is slightly faster if taken on empty stomach
- Duration of Action
- Single-dose effect lasts 6–12 hours; melanocortin receptor occupancy declines steadily
- 4–6 hours (sildenafil half-life approximately 4 hours)
- PT-141 has longer receptor engagement; Viagra's effect is more predictable and shorter
- FDA Approval Status
- Approved 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD)
- Approved 1998 for erectile dysfunction in men; off-label use in women has not shown benefit
- PT-141 is the only FDA-approved treatment for HSDD; Viagra is standard-of-care for male ED
- Adverse Event Profile
- Nausea (40%), flushing (20%), headache (11%), injection site reactions (13%)
- Headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%)
- PT-141 has significantly higher nausea rates; Viagra's side effects are vasodilation-related
- Contraindications
- Uncontrolled hypertension, cardiovascular disease, pregnancy
- Nitrate use (risk of severe hypotension), recent stroke or MI, severe hepatic impairment
- PT-141 carries cardiovascular risk; Viagra is contraindicated with nitrates due to additive vasodilation
- Response in Women
- Statistically significant improvement in SSEs and desire scores in HSDD populations
- No benefit demonstrated in clinical trials. Arousal in women is not primarily vascular
- PT-141 is the only compound with proven female efficacy
- Response in Men
- Modest benefit in psychogenic ED; limited data in vascular ED
- High response rate (60–70%) in vascular and mixed-origin ED
- Viagra is first-line; PT-141 is adjunctive or alternative when PDE5 inhibitors fail